IMPLEMENTATION OF SCIENTIFIC COSTING IN BULK DRUG AND R&D DEPARTMENT OF A PHARMA INDUSTRY Submitted By KAUSTUBH NIJASURE Under the guidance of Prof. P.M. Nayak A PROJECT SUBMITTED IN PART COMPLETITION OF MMS TO THE Vidyalankar Institute Of Technology Wadala (East)‚ Mumbai 400 031 JULY 14th‚ 2008 Executive summary: Centaur Pharmaceuticals Pvt. Ltd. has following divisions: 1. Bulk Drug 2. Formulations 3. Research and Development 4. Clinical Research
Premium Costs Cost Pharmacology
HEC006 Volume 4 Issue 1 March 2006 An ERP Story: Background (A) Case prepared by Professors Carmen BERNIER and Vital ROY‚ as well as Éric BRUNELLE Business Context In 1950‚ when the general insurance company Aux Bons Soins (ABS) was in its early days‚ it offered a full range of general insurance products for individuals residing in the province of Quebec. Over the years‚ Canada has seen a consolidation of its general insurance industry. Three years ago‚ ABS acquired the insurance company
Premium Management Project management
Scope of this report: The scope of the report was based on the annual reports & web site‚ input from interviews of executives of the SQUARE Pharmaceuticals Limited. To analyze the situation in question‚ we worked on focusing on SQUARE Pharmaceuticals Limited and analyzing their objectives‚ market strategies‚ market situations‚ product mixes‚ etc. The analysis was based on the exposed and available information only. In-depth data were not always available on-demand due to some unavailable reasons
Premium Marketing Pharmaceutical industry Pharmacology
representatives in Pharma companies and innovative ways to improve them. Overview: Attrition refers to the reduction in staff and employees of company by normal means. The primary focus is to present the high attrition rate seen in the pharmaceutical market industry‚ its causes and controlling strategy for retention of Pharma sales representatives. Though attrition is a natural phenomena in all industries‚ Indian Pharma marketing industries is worst plagued by it. After IT and BPO‚ Pharma marketing industries
Premium Sales
Corporate finance Project Corporate finance Project Sun pharmaceuticals Sun pharmaceuticals Submitted to : Prof. S.Ramesh Submitted by : Shamili.M (FPB1214/125) Submitted to : Prof. S.Ramesh Submitted by : Shamili.M (FPB1214/125) Type | Public | Traded as | BSE : 524715 NSE: sunpharma | Industry | Pharmaceuticals | Founded | 1983
Premium Pharmaceutical industry Pharmacology
HRM CASE STUDY ON NATIONAL PHARMA Strengths of the analysis of the Discussant 1 • Highlighted the interests and gains of various stakeholders • Highlighted the various deficiencies in execution of the program • Breaking up of problems into appropriate sections : right to information‚ right to be consulted and right to decide jointly • Emphasized the fact that proper research has not been done and how the strategy has been forced by the top management Strengths of the analysis of the Discussant
Premium Management Scientific method Feedback
KALYAN PHARMA LIMITED- CASE ANALYSIS PHARMA SECTOR BACKGROUND: In early 1930’s the medicines were dispensed by doctors and the concept of prescription was not present. Later on the prescription segment grew to 80% by 1970’s and the reason being that number of doctors increased to 250000 as opposed to 110000. Presently the sector is growing at the rate of 8% to 9%. Sales of products has increased from 70 billion to 150 billion. COMPANY BACKGROUND: In 1907‚ Kalyan Pharma Limited (KPL) was
Premium Marketing Sales
Company Background Square Pharmaceuticals Limited has been a household name in Bangladesh since 1958 when it started its operations as a partnership‚ getting incorporated in 1964 and finally getting listed at the stock exchange in 1995. The company has been in the leading front of innovation‚ and continues to introduce new and better medicines in the market every year. Today the 97% of the demands for medicine in the domestic market is catered to by the local pharmaceuticals company and Square
Premium Financial ratios Financial ratio Revenue
assist with my requests for information‚ as well as for his guidance and valuable assistance from the offset of this project. His insights and remarks were of great value. I have furthermore to thank Mr. Ashish Dixit ‚ Senior Executive “GLAXO pharma” who gave and confirmed this permission and encouraged me to go ahead with my thesis. I am bound to thank other staff members for their stimulating support. I am deeply indebted to my Faculty Guide Dr. Nidhi Mathur whose help‚ stimulating suggestions
Premium Pharmaceutical industry Generic drug
valuation of the ‘Big Pharma’ companies has dropped sharply. Discuss the causes of the pharmaceutical industry’s current problems and steps that companies are taking to tackle them. By Ali Asgar Kagzi In 1990s‚ pharmaceutical companies were one of the leading shareholder value creators at the stock market. By 1998 the P/E ratio of the Big Pharma companies was twice that of the global stock market and there was a sudden rush among the investors to have a share of the Pharma pie. But according to
Premium Pharmaceutical industry Pharmacology Drug development